{"brief_title": "ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.", "brief_summary": "The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.", "condition": "Lung Neoplasms", "intervention_type": "Drug", "intervention_name": "cisplatin", "criteria": "Inclusion Criteria: - Have a diagnosis of extensive stage small cell lung cancer and can be treated with chemotherapy. - Have received no prior chemotherapy for your disease. - Have at least one measurable lesion. - have an adequate performance status. - Sign an informed consent form. Exclusion Criteria: - Have previously received chemotherapy for your lung cancer. - Have been treated with a investigational drug within the last 30 days. Have previously completed or withdrawn from this study or any other study investigating ALIMTA. - Have received radiation therapy within the last 1-2 weeks. - Have brain metastasis that is uncontrolled. - Have active infection or other serious condition.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00051506.xml"}